Cargando…

A new generation needle- and adjuvant-free trivalent plague vaccine utilizing adenovirus-5 nanoparticle platform

A plague vaccine with a fusion cassette of YscF, F1, and LcrV encoding genes in an adenovirus-5 vector (rAd5-YFV) is evaluated for efficacy and immune responses in mice. Two doses of the vaccine provides 100% protection when administered intranasally against challenge with Yersinia pestis CO92 or it...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kilgore, Paul B., Sha, Jian, Andersson, Jourdan A., Motin, Vladimir L., Chopra, Ashok K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7846801/ https://www.ncbi.nlm.nih.gov/pubmed/33514747 http://dx.doi.org/10.1038/s41541-020-00275-3

Ejemplares similares

Combinatorial Viral Vector-Based and Live Attenuated Vaccines without an Adjuvant to Generate Broader Immune Responses to Effectively Combat Pneumonic Plague
por: Kilgore, Paul B., et al.
Publicado: (2021)

New Insights into Autoinducer-2 Signaling as a Virulence Regulator in a Mouse Model of Pneumonic Plague
por: Fitts, Eric C., et al.
Publicado: (2016)

Plague vaccines: current developments and future perspectives
por: Feodorova, Valentina A, et al.
Publicado: (2012)

A Bacteriophage-Based, Highly Efficacious, Needle- and Adjuvant-Free, Mucosal COVID-19 Vaccine
por: Zhu, Jingen, et al.
Publicado: (2022)

Immunisation of two rodent species with new live-attenuated mutants of Yersinia pestis CO92 induces protective long-term humoral- and cell-mediated immunity against pneumonic plague
por: Tiner, Bethany L, et al.
Publicado: (2016)

Plague vaccines: new developments in an ongoing search
por: Rosenzweig, Jason A., et al.
Publicado: (2021)

Construction and immune effect of an HPV16/18/58 trivalent therapeutic adenovirus vector vaccine
por: Wan, Bing, et al.
Publicado: (2022)

A Bivalent Anthrax–Plague Vaccine That Can Protect against Two Tier-1 Bioterror Pathogens, Bacillus anthracis and Yersinia pestis
por: Tao, Pan, et al.
Publicado: (2017)

A Potent Trivalent Sialic Acid Inhibitor of Adenovirus Type 37 Infection of Human Corneal Cells**
por: Spjut, Sara, et al.
Publicado: (2011)

Quantification of trivalent non-replicating rotavirus vaccine antigens in the presence of aluminum adjuvant
por: McAdams, David, et al.
Publicado: (2021)

A Bacteriophage T4 Nanoparticle-Based Dual Vaccine against Anthrax and Plague
por: Tao, Pan, et al.
Publicado: (2018)

Mutated and Bacteriophage T4 Nanoparticle Arrayed F1-V Immunogens from Yersinia pestis as Next Generation Plague Vaccines
por: Tao, Pan, et al.
Publicado: (2013)

Matrix-M™ adjuvation broadens protection induced by seasonal trivalent virosomal influenza vaccine
por: Cox, Freek, et al.
Publicado: (2015)

1435. The Cost-Effectiveness of Vaccinating With an Adjuvanted Trivalent Influenza Vaccine for the 65+ Population in Argentina
por: Nguyen, Van, et al.
Publicado: (2018)

Hyaluronic Acid Nanocapsules as a Platform for Needle-Free Vaccination
por: Bussio, Juan I., et al.
Publicado: (2019)

Preclinical Efficacy of a Trivalent Human FcγRI-Targeted Adjuvant-Free Subunit Mucosal Vaccine against Pulmonary Pneumococcal Infection
por: Kumar, Sudeep, et al.
Publicado: (2020)

Marmots and Yersinia pestis Strains in Two Plague Endemic Areas of Tien Shan Mountains
por: Sariyeva, Gulmira, et al.
Publicado: (2019)

Influenza symptoms and their impact on elderly adults: randomised trial of AS03-adjuvanted or non-adjuvanted inactivated trivalent seasonal influenza vaccines
por: van Essen, Gerrit A, et al.
Publicado: (2014)

Combined Adjuvant Formulations Enhanced an Immune Response of Trivalent Foot and Mouth Disease Vaccine in Cattle
por: Ayele, Getu, et al.
Publicado: (2023)

Quillaja brasiliensis nanoparticle adjuvant formulation improves the efficacy of an inactivated trivalent influenza vaccine in mice
por: Silveira, Fernando, et al.
Publicado: (2023)

Non-Inferiority Field Study Comparing the Administrations by Conventional Needle-Syringe and Needle-Free Injectors of a Trivalent Vaccine Containing Porcine Circovirus Types 2a/2b and Mycoplasma hyopneumoniae
por: Cho, Hyejean, et al.
Publicado: (2022)

Pentaplex real‐time PCR for differential detection of Yersinia pestis and Y. pseudotuberculosis and application for testing fleas collected during plague epizootics
por: Bai, Ying, et al.
Publicado: (2020)

Safety, Reactogenicity, and Health-Related Quality of Life After Trivalent Adjuvanted vs Trivalent High-Dose Inactivated Influenza Vaccines in Older Adults: A Randomized Clinical Trial
por: Schmader, Kenneth E., et al.
Publicado: (2021)

Phylogeny and Classification of Yersinia pestis Through the Lens of Strains From the Plague Foci of Commonwealth of Independent States
por: Kutyrev, Vladimir V., et al.
Publicado: (2018)

Yersinia pestis Antigen F1 but Not LcrV Induced Humoral and Cellular Immune Responses in Humans Immunized with Live Plague Vaccine—Comparison of Immunoinformatic and Immunological Approaches
por: Feodorova, Valentina A., et al.
Publicado: (2020)

Engineered trivalent immunogen adjuvanted with a STING agonist confers protection against Trypanosoma cruzi infection
por: Sanchez Alberti, Andrés, et al.
Publicado: (2017)

Helper virus-free gutless adenovirus (HF-GLAd): a new platform for gene therapy
por: Liu, Jida, et al.
Publicado: (2020)

25. Relative Effectiveness of Adjuvanted Trivalent Influenza Vaccine Compared to Egg-Based Trivalent High-Dose Influenza Vaccine among U.S. Older Adults during 2019-20 Influenza Season
por: levin, myron J, et al.
Publicado: (2021)

No more helper adenovirus: production of gutless adenovirus (GLAd) free of adenovirus and replication-competent adenovirus (RCA) contaminants
por: Lee, Dongwoo, et al.
Publicado: (2019)

Studies in the Epidemiology of Plague in H. E. H. the Nizam's Dominions: Comparison of Certain Factors in a Plague-Infected Place with That of Neighbouring Plague-Free Area
por: Rao, S. Raghavender
Publicado: (1940)

Plague Declaration: Plague in Calcutta
Publicado: (1899)

Adverse Events of Interest Following Influenza Vaccination in the First Season of Adjuvanted Trivalent Immunization: Retrospective Cohort Study
por: de Lusignan, Simon, et al.
Publicado: (2022)

Impact of adjuvant: Trivalent vaccine with quadrivalent-like protection against heterologous Yamagata-lineage influenza B virus
por: Myers, Mallory L., et al.
Publicado: (2022)

Relative Vaccine Effectiveness of Adjuvanted Trivalent Influenza Vaccine over Three Consecutive Influenza Seasons in the United States
por: Boikos, Constantina, et al.
Publicado: (2022)

A Case of Plague Successfully Treated with Sulphapyridine
por: Chopra, R. N., et al.
Publicado: (1941)

SSD - a free software for designing multimeric mono-, bi- and trivalent shRNAs
por: de Carli, Gabriel José, et al.
Publicado: (2020)

Trivalent Adenovirus Type 5 HIV Recombinant Vaccine Primes for Modest Cytotoxic Capacity That Is Greatest in Humans with Protective HLA Class I Alleles
por: Migueles, Stephen A., et al.
Publicado: (2011)

Evaluating the Relative Vaccine Effectiveness of Adjuvanted Trivalent Influenza Vaccine Compared to High-Dose Trivalent and Other Egg-Based Influenza Vaccines among Older Adults in the US during the 2017–2018 Influenza Season
por: Pelton, Stephen I., et al.
Publicado: (2020)

Anti-Plague Vaccine in the Treatment of Plague
por: Naidu, T. S.
Publicado: (1930)

996. A Cluster-Randomized Trial of Adjuvanted Trivalent Influenza Vaccine vs. Standard Dose in US Nursing Homes
por: Gravenstein, Stefan, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_4aohv08iffd2boqds0pie4qjm6